Browse our 650+ Publications
Latest Publications
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
Shah P, et al.
Journal for ImmunoTherapy of Cancer
February 2022
Authors and Affiliates
Parin Shah #,1, Marie-Andrée Forget #,1,2, Meredith L Frank #,3, Peixin Jiang 3, Donastas Sakellariou-Thompson 2, Lorenzo Federico 1, Roohussaba Khairullah 3, Chantal Alexia Neutzler 2, Ignacio Wistuba 3,4, Chi-Wan B Chow 4, Yan Long 4, Junya Fujimoto 4, Shiaw-Yih Lin 5, Anirban Maitra 4, Marcelo V Negrao 3, Kyle Gregory Mitchell 6, Annikka Weissferdt 7, Ara A Vaporciyan 6, Tina Cascone 3, Jack A Roth 6, Jianjun Zhang 3, Boris Sepesi 6, Don L Gibbons 3, John V Heymach 3, Cara L Haymaker 4, Daniel J McGrail 8, Alexandre Reuben 9, Chantale Bernatchez 10,2;
1 Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
2 Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
3 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
4 Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
5 Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
6 Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
7 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
8 Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.
9 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.
10 Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.
# Contributed equally.
Multiple early factors anticipate post-acute COVID-19 sequelae
Su Y, et al.
Cell
February 2022
Authors and Affiliates
Yapeng Su 1, Dan Yuan 2, Daniel G Chen 3, Rachel H Ng 2, Kai Wang 4, Jongchan Choi 4, Sarah Li 4, Sunga Hong 4, Rongyu Zhang 2, Jingyi Xie 5, Sergey A Kornilov 4, Kelsey Scherler 4, Ana Jimena Pavlovitch-Bedzyk 6, Shen Dong 7, Christopher Lausted 4, Inyoul Lee 4, Shannon Fallen 4, Chengzhen L Dai 4, Priyanka Baloni 4, Brett Smith 4, Venkata R Duvvuri 4, Kristin G Anderson 8, Jing Li 6, Fan Yang 9, Caroline J Duncombe 10, Denise J McCulloch 11, Clifford Rostomily 4, Pamela Troisch 4, Jing Zhou 12, Sean Mackay 12, Quinn DeGottardi 13, Damon H May 13, Ruth Taniguchi 13, Rachel M Gittelman 13, Mark Klinger 13, Thomas M Snyder 13, Ryan Roper 4, Gladys Wojciechowska 14, Kim Murray 4, Rick Edmark 4, Simon Evans 4, Lesley Jones 4, Yong Zhou 4, Lee Rowen 4, Rachel Liu 4, William Chour 4, Heather A Algren 15, William R Berrington 15, Julie A Wallick 15, Rebecca A Cochran 15, Mary E Micikas 15, ISB-Swedish COVID-19 Biobanking Unit 4; Terri Wrin 16, Christos J Petropoulos 16, Hunter R Cole 17, Trevan D Fischer 17, Wei Wei 4, Dave S B Hoon 17, Nathan D Price 4, Naeha Subramanian 18, Joshua A Hill 19, Jennifer Hadlock 4, Andrew T Magis 4, Antoni Ribas 20, Lewis L Lanier 21, Scott D Boyd 9, Jeffrey A Bluestone 7, Helen Chu 22, Leroy Hood 23, Raphael Gottardo 24, Philip D Greenberg 8, Mark M Davis 25, Jason D Goldman 26, James R Heath 27;
1 Institute for Systems Biology, Seattle, WA 98109, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: suyapeng.tju@gmail.com.
2 Institute for Systems Biology, Seattle, WA 98109, USA; Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
3 Institute for Systems Biology, Seattle, WA 98109, USA; Department of Microbiology and Department of Informatics, University of Washington, Seattle, WA 98195, USA.
4 Institute for Systems Biology, Seattle, WA 98109, USA.
5 Institute for Systems Biology, Seattle, WA 98109, USA; Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA 98105, USA.
6 Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
7 Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.
8 Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Departments of Immunology and Medicine, University of Washington, Seattle, WA 98109, USA.
9 Department of Pathology, Stanford University, Stanford, CA 94304, USA.
10 Division of Global Health, University of Washington, Seattle, WA 98105, USA.
11 Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
12 Isoplexis Corporation, Branford, CT 06405, USA.
13 Adaptive Biotechnologies, Seattle, WA 98109, USA.
14 Institute for Systems Biology, Seattle, WA 98109, USA; Medical University of Białystok, Białystok 15089, Poland.
15 Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, WA 98109, USA; Providence St. Joseph Health, Renton, WA 98057, USA.
16 Monogram Biosciences, South San Francisco, CA 94080, USA.
17 St. John's Cancer Institute at Saint John's Health Center, Santa Monica, CA 90404, USA.
18 Institute for Systems Biology, Seattle, WA 98109, USA; Department of Global Heath and Department of Immunology, University of Washington, Seattle, WA 98109, USA.
19 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
20 Department of Medicine, University of California, Los Angeles, and Parker Institute for Cancer Immunotherapy, Los Angeles, CA 90095, USA.
21 Department of Microbiology and Immunology, University of California, San Francisco, and Parker Institute for Cancer Immunotherapy, San Francisco, CA 94143, USA.
22 Division of Global Health, University of Washington, Seattle, WA 98105, USA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
23 Institute for Systems Biology, Seattle, WA 98109, USA; Providence St. Joseph Health, Renton, WA 98057, USA.
24 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Statistics, University of Washington, Seattle, WA 98195, USA; Biomedical Data Sciences, Lausanne University Hospital, University of Lausanne, Lausanne, 1011, Switzerland.
25 Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
26 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA; Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, WA 98109, USA; Providence St. Joseph Health, Renton, WA 98057, USA. Electronic address: jason.goldman@swedish.org.
27 Institute for Systems Biology, Seattle, WA 98109, USA; Department of Bioengineering, University of Washington, Seattle, WA 98105, USA. Electronic address: jim.heath@isbscience.org.
The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders
Pagliuca S, et al.
Blood
February 2022
Authors and Affiliates
Simona Pagliuca 1,2, Carmelo Gurnari 1,3, Hassan Awada 1, Ashwin Kishtagari 1, Sunisa Kongkiatkamon 1, Laila Terkawi 1, Misam Zawit 1, Yihong Guan 1, Thomas LaFramboise 4, Babal K Jha 1, Bhumika J Patel 5, Betty K Hamilton 6, Navneet S Majhail 6, Sofie Lundgren 7,8, Satu Mustjoki 7,8,9, Yogen Saunthararajah 1, Valeria Visconte 1, Timothy A Chan 10, Chao-Yie Yang 11, Tobias L Lenz 12,13, Jaroslaw P Maciejewski 1;
1 Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH.
2 University of Paris, Paris, France.
3 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
4 Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH.
5 Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH.
6 Blood and Marrow Transplant Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH.
7 Hematology Research Unit Helsinki, University of Helsinki-Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
8 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
9 ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
10 Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH.
11 Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN.
12 Research Group for Evolutionary Immunogenomics, Max Planck Institute for Evolutionary Biology, Plön, Germany; and.
13 Research Unit for Evolutionary Immunogenomics, Department of Biology, University of Hamburg, Hamburg, Germany.
HLA-dependent variation in SARS-CoV-2 CD8+ T cell cross-reactivity with human coronaviruses
Buckely PR, et al.
immunology
February 2022
Authors and Affiliates
Paul R Buckley 1,2, Chloe H Lee 1,2, Mariana Pereira Pinho 1, Rosana Ottakandathil Babu 1,2, Jeongmin Woo 1,2, Agne Antanaviciute 1,2, Alison Simmons 1, Graham Ogg 1, Hashem Koohy 1,2;
1 MRC Human Immunology Unit, Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
2 MRC WIMM Centre for Computational Biology, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA.
Wang J, et al.
Leukemia & Lymphoma
February 2022
Authors and Affiliates
Jiasheng Wanga , Raul Arroyo-Suarezb, Srilatha Dasarib, Kanithra Sekaranb and William Tsec
aDepartment of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; bDepartment of Internal Medicine, MetroHealth Medical Center, Cleveland, OH, USA; cDepartment of Hematology and Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Cavo M, et al.
Blood
February 2022
Authors and Affiliates
Michele Cavo,1 Jesus San-Miguel,2 Saad Z. Usmani,3 Katja Weisel,4 Meletios A. Dimopoulos,5 Herve Avet-Loiseau, 6 Bruno Paiva,2 Nizar J. Bahlis,7 Torben Plesner,8 Vania Hungria,9 Philippe Moreau,10 Maria-Victoria Mateos,11 Aurore Perrot,12 Shinsuke Iida,13 Thierry Facon,14 Shaji Kumar,15 Niels W. C. J. van de Donk,16 Pieter Sonneveld,17 Andrew Spencer,18 Maria Krevvata,19 Christoph Heuck,19 Jianping Wang,20 Jon Ukropec,21 Rachel Kobos,19 Steven Sun,20 Mia Qi,20 and Nikhil Munshi22,23
1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli ”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, Bologna, Italy; 2
Clınica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC, Pamplona, Spain; 3Levine Cancer Institute/Atrium Health, Charlotte, NC; 4Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5National and Kapodistrian University of Athens, Athens, Greece; 6Unite de Genomique du
Myelome, IUC-Oncopole, Toulouse, France; 7Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada; 8Vejle Hospital and University of Southern Denmark, Vejle, Denmark; 9
Clinica Medica Sao Germano, S ao Paulo, Brazil; 10Hematology, University Hospital Hotel-Dieu, CHU Nantes, Nantes, France; 11University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; 12Hematology Department, University Cancer Institute IUCT, Toulouse, France; 13Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku
Nagoya, Japan; 14University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 15Department of Hematology, Mayo Clinic Rochester, Rochester, MN; 16Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; 17Erasmus MC, Rotterdam, The Netherlands; 18Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia; 19Janssen Research &
Development, LLC, Spring House, PA; 20Janssen Research & Development, LLC, Raritan, NJ; 21Janssen Global Medical Affairs, Horsham, PA; 22Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 23Veterans Administration Boston Healthcare System, West Roxbury, MA
Decade-long leukaemia remissions with persistence of CD4 + CAR T cells
Melenhorst JJ, et al.
February 2022
Authors and Affiliates
J Joseph Melenhorst #,1,2,3,4,5, Gregory M Chen #,6, Meng Wang #,7,8,9, David L Porter #,9,10, Changya Chen 11,12, McKensie A Collins 7,8,9,13, Peng Gao 11,12, Shovik Bandyopadhyay 13, Hongxing Sun 7,8,9, Ziran Zhao 7,8,9, Stefan Lundh 7,8,9, Iulian Pruteanu-Malinici 14, Christopher L Nobles 15, Sayantan Maji 7,8,9, Noelle V Frey 9, Saar I Gill 9, Lifeng Tian 7,9, Irina Kulikovskaya 7,8,9, Minnal Gupta 7,8,9, David E Ambrose 7,8,9, Megan M Davis 7,8,9, Joseph A Fraietta 7,8,9,15, Jennifer L Brogdon 14, Regina M Young 7,8,9, Anne Chew 7,8,9, Bruce L Levine 7,8,9, Donald L Siegel 7,8,16, Cécile Alanio 17,18,19, E John Wherry 17,18,19, Frederic D Bushman 15, Simon F Lacey 7,8,9, Kai Tan 20,21,22,23,24, Carl H June 25,26,27,28,29;
1 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
3 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
4 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu.
5 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. mej@pennmedicine.upenn.edu.
6 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA.
7 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
8 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
9 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
10 Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
11 Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
12 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
13 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA.
14 Novartis Institute for Biomedical Research, Cambridge, MA, USA.
15 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
16 Department of Transfusion Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
17 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
18 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA.
19 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
20 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu.
21 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu.
22 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu.
23 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. tank1@chop.edu.
24 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu.
25 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
26 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
27 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
28 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
29 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. cjune@upenn.edu.
# Contributed equally.
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
Chun B, et al.
Journal for ImmunoTherapy of Cancer
February 2022
Authors and Affiliates
Brie Chun 1, Joanna Pucilowska 2, ShuChing Chang 3, Isaac Kim 1, Benjamin Nikitin 1, Yoshinobu Koguchi 1, William L Redmond 1, Brady Bernard 1 4, Venkatesh Rajamanickam 1,4, Nathan Polaske 5, Paul A Fields 5, Valerie Conrad 1, Mark Schmidt 1, Walter J Urba 1, Alison K Conlin 1, Heather L McArthur 6, David B Page 7;
1 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA.
2 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
3 Medical Data Research Center, Providence St Joseph Health, Portland, Oregon, USA.
4 Computational Immuno-Oncology and Bioinformatics Core, Earle A. Chiles Research Institute, Portland, Oregon, USA.
5 Adaptive Biotechnologies Corp, Seattle, Washington, USA.
6 Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
7 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA david.page2@providence.org.
Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development
Edgar JM, et al.
npj Regenerative Medicine
February 2022
Authors and Affiliates
John M Edgar 1, Yale S Michaels 1, Peter W Zandstra 2,3;
1 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
2 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. peter.zandstra@ubc.ca.
3 Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada. peter.zandstra@ubc.ca.